Targets › NGF
3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 4; Oncology, Ophthalmology, Neurology; next expected readout Dec 2026.
Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signaling cascades to regulate neuronal proliferation, differentiation and survival (Probable). (UniProt, P01138)
Open in Phaseline: the race on NGF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The Third Affiliated hospital of Zhejiang Chinese Medical University | Nerve growth factor (NGF) Neurotrophic factor to promote nerve regeneration and functional recovery | NGF | Phase 4 | Ischemic Stroke | Dec 2027 |
| Krystal Biotech | KB801 Replication-defective, non-integrating HSV-1 vector delivering human nerve growth factor ( | NGF | Phase 1 | Neurotrophic Keratitis | Dec 2026 |
| Shenyang Sunshine Pharmaceutical | SSS40 Humanized nerve growth factor (NGF) antibody | NGF | Phase 1 | Cancer Pain | – |
Cancer Pain (1) Neurotrophic Keratitis (1) Ischemic Stroke (1)
antibody (1), protein or peptide (1), small molecule (1)
Shenyang Sunshine Pharmaceutical (1) Krystal Biotech (1) The Third Affiliated hospital of Zhejiang Chinese Medical University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.